Last reviewed · How we verify
NCT06066359
Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma
Phase 1, PHASE2 trial testing Fludarabine phosphate in Myeloma in 44 participants. Currently enrolling.
31 August 2026
Quick facts
| Lead sponsor | M.D. Anderson Cancer Center |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 44 |
| Start date | 30 November 2023 |
| Primary completion | 31 August 2026 |
| Estimated completion | 31 August 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Fludarabine phosphate (FLUDARABINE PHOSPHATE) — full drug profile →
- Cyclophosphamide (cyclophosphamide) — full drug profile →
- NY-ESO-1 TCR/IL-15 NK — full drug profile →
Conditions studied
- Myeloma — all drugs for Myeloma →
Sponsor
M.D. Anderson Cancer Center — full company profile →
Who can join
18 and older, any sex, with Myeloma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help to control the disease.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
NY-ESO-1 antigen: A promising frontier in cancer immunotherapy.
Alsalloum A, Shevchenko JA, Sennikov S. · · 2024 · cited 16× · PMID 39275923 · DOI 10.1002/ctm2.70020 -
Emerging roles of type 1 innate lymphoid cells in tumour pathogenesis and cancer immunotherapy.
Verner JM, Arbuthnott HF, Ramachandran R, Bharadwaj M, et al · · 2024 · cited 9× · PMID 38745765 · DOI 10.37349/etat.2024.00219 -
Harnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy.
Douka S, Papamoschou V, Raimo M, Mastrobattista E, et al · · 2024 · cited 6× · PMID 39339180 · DOI 10.3390/pharmaceutics16091143
Verify or expand the search:
- PubMed search for NCT06066359
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fludarabine phosphate
Trials testing the same drug.
- NCT06345495 — High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly · Phase 2 · recruiting
- NCT06434363 — Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Di · Phase 1, PHASE2 · recruiting
- NCT06383572 — Phase I/II Study of Engineered T Cell Receptor-Modified NK Cells Targeting PRAME in Conjunction With Lymphodepleting Che · Phase 1, PHASE2 · recruiting
- NCT06083883 — Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1 · Phase 1 · recruiting
- NCT06043323 — A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination · Phase 2 · recruiting
Other recruiting trials for Myeloma
Currently open trials in the same condition.
- NCT06487247 — HEME Home Transfusion Program · NA · recruiting
- NCT07106671 — A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma · Phase 2 · recruiting
- NCT07052916 — A Music Therapy Study for Blood Cancer Survivors With Cognitive Difficulties · NA · recruiting
- NCT07202078 — Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) · Phase 2, PHASE3 · recruiting
- NCT07202052 — Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) · Phase 2, PHASE3 · recruiting
Other M.D. Anderson Cancer Center trials
Trials by the same sponsor.
- NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
- NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
- NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06066359 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
- Last refreshed: 11 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06066359.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing